188 related articles for article (PubMed ID: 28489852)
1. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature.
Fredriksson NJ; Elliott K; Filges S; Van den Eynden J; Ståhlberg A; Larsson E
PLoS Genet; 2017 May; 13(5):e1006773. PubMed ID: 28489852
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
4. Highly recurrent TERT promoter mutations in human melanoma.
Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
[TBL] [Abstract][Full Text] [Related]
5. Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome.
Poulos RC; Thoms JA; Shah A; Beck D; Pimanda JE; Wong JW
Mol Cancer Res; 2015 Aug; 13(8):1218-26. PubMed ID: 26082173
[TBL] [Abstract][Full Text] [Related]
6. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
7. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
8. Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.
Colebatch AJ; Di Stefano L; Wong SQ; Hannan RD; Waring PM; Dobrovic A; McArthur GA; Papenfuss AT
Oncotarget; 2016 Oct; 7(41):66569-66585. PubMed ID: 27611953
[TBL] [Abstract][Full Text] [Related]
9.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
10. Intragenomic variability and extended sequence patterns in the mutational signature of ultraviolet light.
Lindberg M; Boström M; Elliott K; Larsson E
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20411-20417. PubMed ID: 31548379
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
12. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
14. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in cancer development.
Heidenreich B; Rachakonda PS; Hemminki K; Kumar R
Curr Opin Genet Dev; 2014 Feb; 24():30-7. PubMed ID: 24657534
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
17. Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes.
Perera D; Poulos RC; Shah A; Beck D; Pimanda JE; Wong JW
Nature; 2016 Apr; 532(7598):259-63. PubMed ID: 27075100
[TBL] [Abstract][Full Text] [Related]
18. Impact of cancer mutational signatures on transcription factor motifs in the human genome.
Yiu Chan CW; Gu Z; Bieg M; Eils R; Herrmann C
BMC Med Genomics; 2019 May; 12(1):64. PubMed ID: 31109337
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
